Dohj LLC Trims Stake in IQVIA Holdings Inc. (NYSE:IQV)

Dohj LLC reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 59.1% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 1,667 shares of the medical research company’s stock after selling 2,407 shares during the period. Dohj LLC’s holdings in IQVIA were worth $422,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Wealth Enhancement Advisory Services LLC raised its stake in IQVIA by 5.4% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 5,898 shares of the medical research company’s stock valued at $1,492,000 after acquiring an additional 300 shares during the last quarter. Riverview Trust Co purchased a new stake in IQVIA during the 1st quarter valued at approximately $32,000. Central Valley Advisors LLC raised its stake in IQVIA by 9.5% during the 1st quarter. Central Valley Advisors LLC now owns 5,612 shares of the medical research company’s stock valued at $1,419,000 after acquiring an additional 488 shares during the last quarter. Nova R Wealth Inc. purchased a new position in shares of IQVIA during the 1st quarter worth approximately $364,000. Finally, Capital Planning LLC purchased a new position in shares of IQVIA during the 1st quarter worth approximately $253,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Trading Up 0.7 %

Shares of IQV stock traded up $1.57 during mid-day trading on Thursday, hitting $212.75. 942,715 shares of the company’s stock were exchanged, compared to its average volume of 1,027,411. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The stock has a 50-day simple moving average of $224.55 and a two-hundred day simple moving average of $230.21. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02. The stock has a market cap of $38.76 billion, a price-to-earnings ratio of 29.06, a PEG ratio of 1.93 and a beta of 1.53.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, May 2nd. The medical research company reported $2.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.19 by $0.11. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The business had revenue of $3.74 billion for the quarter, compared to analysts’ expectations of $3.69 billion. Equities analysts expect that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on IQV. StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a research note on Friday, June 21st. Robert W. Baird cut their target price on IQVIA from $254.00 to $245.00 and set a “neutral” rating for the company in a research note on Friday, May 3rd. Truist Financial cut their target price on IQVIA from $297.00 to $292.00 and set a “buy” rating for the company in a research note on Friday, May 3rd. The Goldman Sachs Group started coverage on IQVIA in a research note on Thursday, June 6th. They issued a “buy” rating and a $270.00 price objective for the company. Finally, Evercore ISI dropped their price objective on IQVIA from $275.00 to $250.00 and set an “outperform” rating for the company in a research note on Friday, May 3rd. Four investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $258.40.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.